Jonathan Brammer, MD
The treatment landscape for patients with T-cell lymphoma continues to evolve, with ongoing advances that include the utilization of brentuximab vedotin (Adcetris), according to Jonathan Brammer, MD.
on Hematologic Malignancies, Brammer, a hematologist at The Ohio State University Comprehensive Cancer Center, discussed exciting therapeutic developments for patients with T-cell lymphoma.
OncLive: Can you provide an overview of your presentation on T-cell lymphoma?
T-cell lymphomas have been an area of limited progress and poor overall prognosis. Over the past several years, we’ve had some exciting new developments. One of the most exciting developments is brentuximab vedotin, which is now being utilized for patients with relapsed CD30-positive anaplastic large cell lymphoma, some of whom have long-term durable remissions. Brentuximab vedotin is also highly effective in patients with relapsed cutaneous T-cell lymphoma, as well.
... to read the full story